Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | PRKACA | P17612 | 2/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816956 | 0.95 | MAPK1 (0.62) | MMP13EPHX2NR1H4HDAC1HDAC2 | |
| SCHEMBL3819230 | 0.88 | L3MBTL1 (0.56) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3817088 | 0.88 | MEN1 (0.51) | HDAC1MAPK1MAP4K4ADORA2ARAB9A | |
| SCHEMBL14009849 | 0.86 | MMP13 (0.61) | MMP13EPHX2NR1H4HDAC1HDAC2 | |
| SCHEMBL3814785 | 0.85 | HDAC1 (0.66) | EPHX2NR1H4HDAC1HDAC2HDAC8 | |
| SCHEMBL3818520 | 0.84 | CYP3A4 (0.49) | MMP13HDAC1HDAC2HDAC3HDAC11 | |
| SCHEMBL3811289 | 0.83 | ROCK2 (0.64) | HDAC1MAPK1PRKACAROCK1ROCK2 | |
| SCHEMBL3818967 | 0.82 | ROCK2 (0.47) | HDAC1HDAC2HDAC8HDAC6HDAC5 | |
| SCHEMBL3810616 | 0.82 | ROCK1 (0.55) | MMP13MAPK1ROCK1ROCK2ADORA2A | |
| SCHEMBL3816834 | 0.82 | ROCK1 (0.56) | MAPK1ROCK1ROCK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713775-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | claimed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | claimed |
| EP-1713775-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005074643-A2 | BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | claimed |
| EP-1713775-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| EP-1713775-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005074643-A2 | BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275062-A1 | Chemical Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | MMP13 3272/4885EPHX2 759/4885NR1H4 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.